| Current progress of siRNA/shRNA therapeutics in clinical trials JC Burnett, JJ Rossi, K Tiemann Biotechnology journal 6 (9), 1130-1146, 2011 | 650 | 2011 |
| RNAi‐based therapeutics–current status, challenges and prospects K Tiemann, JJ Rossi EMBO molecular medicine 1 (3), 142-151, 2009 | 371 | 2009 |
| Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells J Zhou, K Tiemann, P Chomchan, J Alluin, P Swiderski, J Burnett, ... Nucleic acids research 41 (7), 4266-4283, 2013 | 90 | 2013 |
| Antisense 2′-deoxy, 2′-fluoroarabino nucleic acid (2′ F-ANA) oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids N Souleimanian, GF Deleavey, H Soifer, S Wang, K Tiemann, MJ Damha, ... Molecular Therapy Nucleic Acids 1, 2012 | 85 | 2012 |
| MicroRNAs act complementarily to regulate disease-related mRNA modules in human diseases S Chavali, S Bruhn, K Tiemann, P Sætrom, F Barrenäs, T Saito, K Kanduri, ... Rna 19 (11), 1552-1562, 2013 | 61 | 2013 |
| Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial F Chiuppesi, JA Zaia, PH Frankel, R Stan, J Drake, B Williams, AM Acosta, ... The Lancet Microbe 3 (4), e252-e264, 2022 | 46 | 2022 |
| Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance GC Rivera-Gonzalez, AP Droop, HJ Rippon, K Tiemann, D Pellacani, ... Nucleic acids research 40 (11), 4825-4840, 2012 | 44 | 2012 |
| Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis K Tiemann, C Garri, SB Lee, PD Malihi, M Park, RM Alvarez, LP Yap, ... Oncogene 38 (16), 3003-3018, 2019 | 35 | 2019 |
| Dual-targeting siRNAs K Tiemann, B Höhn, A Ehsani, SJ Forman, JJ Rossi, P Sætrom Rna 16 (6), 1275-1284, 2010 | 33 | 2010 |
| JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. MP Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes ... Mol Cancer Ther 16 (8), 1645-1657, 2017 | 22 | 2017 |
| A link between integral membrane protein expression and simulated integration efficiency SS Marshall, MJM Niesen, A Müller, K Tiemann, SM Saladi, RP Galimidi, ... Cell Reports 16 (8), 2169-2177, 2016 | 22 | 2016 |
| Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines K Tiemann, JV Alluin, A Honegger, P Chomchan, S Gaur, Y Yun, ... Leukemia & lymphoma 52 (11), 2148-2154, 2011 | 18 | 2011 |
| Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2) C Garri, S Howell, K Tiemann, A Tiffany, F Jalali-Yazdi, MM Alba, JE Katz, ... Oncotarget 9 (44), 27363, 2018 | 12 | 2018 |
| RNA aptamers against BAFF-R as cell-type specific delivery agents and methods for their use J Rossi, K Tiemann, J Zhou, B Vallazza US Patent 9,006,416, 2015 | 4 | 2015 |
| Promising safety and anti-lymphoma efficacy of autologous Pmb-CT01 (BAFFRCAR T cell) therapy in a first-in-human phase 1 study LE Budde, MM Del Real, JH Baird, L Chen, JY Song, S Kambhampati, ... Blood 142, 221, 2023 | 3 | 2023 |
| Assessment of resistance to tyrosine kinase inhibitors by an interrogation of signal transduction pathways by antibody arrays K Tiemann, C Garri, J Wang, L Clarke, K Kani Journal of Visualized Experiments: JoVE, 57779, 2018 | 2 | 2018 |
| RNA aptamers against BAFF-R as cell-type specific delivery agents and methods for their use J Rossi, K Tiemann, J Zhou, B Vallazza US Patent 9,353,374, 2016 | 1 | 2016 |
| Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis DT Samuels, JM Yao, Y Samara, D Yang, S Mokhtari, K Tiemann, ... Frontiers in Immunology 16, 1543099, 2025 | | 2025 |
| Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation S Arslan, A Desai, D Yang, S Mokhtari, K Tiemann, S Otoukesh, Y Samara, ... Transplantation and Cellular Therapy 30 (10), 1013. e1-1013. e12, 2024 | | 2024 |
| PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed … LE Budde, M Del Real, JH Baird, L Chen, JY Song, X Wang, ... Journal of Clinical Oncology 42 (16_suppl), 6534-6534, 2024 | | 2024 |
John C. BurnettAssociate Professor at University of Miami and Sylvester Comprehensive Cancer CenterEmail yang diverifikasi di miami.edu
